Skip to main
HSCS
HSCS logo

HSCS Stock Forecast & Price Target

HSCS Analyst Ratings

Based on 2 analyst ratings
Strong Buy
Strong Buy 100%
Buy 0%
Hold 0%
Sell 0%
Strong Sell 0%

Bulls say

HeartSciences Inc. has demonstrated a positive financial outlook through the upward revision of its fiscal year 2026 EPS estimate to $(4.17), indicating improved expectations for the company's financial performance compared to the previous estimate of $(8.63). The anticipated approval of the MyoVista device, along with the rollout of the MyoVista Insights cloud software platform and the expected FDA approval of its first diagnostic algorithm in the first half of 2026, positions the company for significant market opportunities in the cardiac diagnostic field. Additionally, the company's reaffirmation of regulatory timelines highlights its commitment to achieving critical milestones that could enhance its competitive edge in the growing healthcare sector.

Bears say

HeartSciences Inc. faces multiple fundamental challenges that contribute to a negative outlook on its stock, including significant balance sheet and liquidity risks. The company's future revenue projections for FY2026 have been drastically reduced from $1.2 million to only $0.1 million, primarily due to delays in obtaining FDA regulatory approvals. Additionally, the company's reliance on successful clinical trials and commercialization of its AI-ECG diagnostic solutions highlights potential vulnerabilities amidst increasing competition and fluctuating investor sentiment in the healthcare sector.

HSCS has been analyzed by 2 analysts, with a consensus rating of Strong Buy. 100% of analysts recommend a Strong Buy, 0% recommend Buy, 0% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Heart Test Laboratories Inc and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Heart Test Laboratories Inc (HSCS) Forecast

Analysts have given HSCS a Strong Buy based on their latest research and market trends.

According to 2 analysts, HSCS has a Strong Buy consensus rating as of Oct 14, 2025. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $10.50, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $10.50, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Heart Test Laboratories Inc (HSCS)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.